Citigroup Issues Pessimistic Forecast for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT) had its price objective dropped by equities research analysts at Citigroup from $10.50 to $10.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s target price suggests a potential upside of 45.14% from the company’s current price.

HCAT has been the topic of a number of other reports. Evercore ISI lifted their price target on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. KeyCorp raised Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective for the company in a report on Wednesday. Stephens lifted their price objective on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a report on Thursday, November 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a report on Friday, October 4th. Finally, Royal Bank of Canada boosted their price target on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.45.

Health Catalyst Trading Down 6.4 %

Shares of HCAT stock opened at $6.89 on Friday. The business’s 50 day moving average is $7.79 and its two-hundred day moving average is $7.53. Health Catalyst has a twelve month low of $5.42 and a twelve month high of $11.41. The company has a market capitalization of $419.24 million, a P/E ratio of -5.10 and a beta of 1.36. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. During the same quarter last year, the business posted ($0.22) earnings per share. The company’s revenue for the quarter was up 3.5% compared to the same quarter last year. Equities analysts forecast that Health Catalyst will post -0.33 EPS for the current year.

Insider Activity

In other news, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.51, for a total value of $39,119.59. Following the completion of the sale, the chief operating officer now owns 91,253 shares of the company’s stock, valued at $685,310.03. This represents a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Duncan Gallagher sold 4,500 shares of the company’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $6.98, for a total value of $31,410.00. Following the completion of the sale, the director now directly owns 74,438 shares of the company’s stock, valued at $519,577.24. The trade was a 5.70 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 76,051 shares of company stock valued at $612,614 over the last quarter. Company insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. First Light Asset Management LLC raised its stake in Health Catalyst by 438.5% during the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after buying an additional 3,221,408 shares in the last quarter. Millennium Management LLC grew its holdings in Health Catalyst by 96.3% in the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after buying an additional 1,184,131 shares in the last quarter. Nepsis Inc. grew its holdings in Health Catalyst by 67.9% in the 3rd quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock worth $17,131,000 after buying an additional 851,448 shares in the last quarter. Fred Alger Management LLC bought a new position in Health Catalyst in the 3rd quarter worth approximately $6,858,000. Finally, Portolan Capital Management LLC bought a new position in Health Catalyst in the 3rd quarter worth approximately $5,402,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.